⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RARE News
Ultragenyx Pharmaceutical Inc.
Andelyn and Its Curator® Platform Achieve First FDA-Approved Commercial Gene Therapy Manufacturing Milestone Following FDA Approval of Ultragenyx's FAYUVITM to Treat Sanfilippo Syndrome Type A (MPS IIIA)
prnewswire.com
RARE
Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)
globenewswire.com
ABEO
RARE
Form 8-K
sec.gov
RARE
Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)
globenewswire.com
RARE
FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A
globenewswire.com
RARE
Bronstein, Gewirtz & Grossman, LLC Encourages Ultragenyx Pharmaceutical Inc. (RARE) Stockholders to Inquire about Securities Investigation
accessnewswire.com
RARE
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
prnewswire.com
RARE
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Ultragenyx Pharmaceutical Inc. (RARE) and Encourages Investors to Learn More About the Investigation
accessnewswire.com
RARE
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
accessnewswire.com
RARE
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
globenewswire.com
RARE